**Erythema Ab igne**

Joshua Haron Abasszade,1,2 Timothy Abrahams,1 Chih Chien Kuan,3 Lik Hui Lau1,2

---

**Department of General Medicine, Monash Health, Clayton, Victoria, Australia**

**Department of General Medicine, Northern Health, Epping, Victoria, Australia**

**Department of Anatomical Pathology, Monash Health, Clayton, Victoria, Australia**

**Correspondence to**
Dr Lik Hui Lau;
lkhuiwilliam.lau@monashhealth.org

**Accepted 28 April 2023**

---

**DESCRIPTION**

A man in his late 80’s with chronic end-stage kidney disease (ESKD), presumed secondary to renovascular causes and a horseshoe kidney, presented to an Australian tertiary hospital with a 1-month history of worsening back pain and a new non-pruritic, painless rash across his lower back. This coincided with receiving an iron infusion prior to presentation. Other than being recently commenced on a buprenorphine patch with paracetamol and oxycodone for back pain 2 weeks prior to admission, there were no other changes to regular medications. On examination, there was evidence of a brown, hyperpigmented, non-blanching, smooth, web-like rash spanning across his lower back (figure 1).

A CT scan of his lumbar spine revealed a vertebral fracture at L3 and multiple spinal lytic lesions. Full blood examination demonstrated a microcytic anaemia: haemoglobin 83 g/L (125–175 g/L) and mean corpuscular volume 69 fl (78–98 fl). Eosinophils were 0.04×10⁹/L (0.00–0.50×10⁹/L) suggesting this rash was not secondary to a drug reaction. Biochemistry revealed ESKD with serum creatinine 834 µmol/L (60–100 µmol/L), eGFR 4 mL/min (>90 mL/min) and mild hypercalcemia 2.75 mmol/L (2.10–2.60 mmol/L). Free lambda light chains were significantly elevated at 27456 mg/mL (5.7–26.3 mg/mL) while free kappa light chains were 23.4 mg/mL (3.3–19.4 mg/mL); a kappa/lambda ratio of <0.001. Serum protein electrophoresis showed an IgA monoclonal gammopathy. Total IgA and beta-2-microglobulin levels were significantly elevated at 46.2 g/L (0.8–4.5 g/L) and 75.5 mg/mL (1.4–3.2 mg/mL), respectively, with a low albumin 25 g/L (32–47 g/L). A bone

---

**Figure 1** Clinical photograph demonstrating erythema ab igne rash spanning across the lower back.

---

**Figure 2** Histopathology of biopsy. (A) Epidermis with thinned suprapapillary plates, epidermal atrophy and some subtle patchy basal vacuolar degenerative change (open arrows) with associated overlying surface hyperkeratosis. (B) Sweat glands in the skin with elastic fibres arranged in strands and globules indicative of prominent periadnexal elastosis within the dermis (arrows). (C, D) Sparse perivascular lymphocytic infiltrate (arrows) and subtle pigmentary incontinence.
marrow aspirate and trephine confirmed diagnosis of IgA multiple myeloma with presence of clonal bone marrow plasma cells of 80%.

A skin biopsy performed of his lower back demonstrated histopathological findings of basal vacular degeneration and epidermal atrophy with overlying surface hyperkeratosis (figure 2) typically seen with erythema ab igne (EAI). Eosinophilic and neutrophilic infiltrates were not seen, making the diagnosis of drug reactions and neutrophilic dermatosis, respectively, less likely. On targeted history, the patient admitted to applying a hot water bottle directly onto his back daily to relieve his pain over the preceding month. The patient was advised to avoid further use of hot water bottles or direct heat exposure.

Management of his myeloma was conducted by the haematology team. Unfortunately, the patient died shortly after commencing treatment with bortezomib and dexamethasone due to complications of ESKD and a superimposed hospital acquired pneumonia. Resolution of EAI was unable to be realised. Given that the rash preceded commencement of bortezomib and dexamethasone and that the patient was not on any other chemotherapy regimens, drug reactions to those medications and flagellate pigmentation were thought to be an unlikely cause.

EAI typically presents as an asymmetrical, hyperpigmented and reticulated rash that results from repeated heat contact on the skin.1–3 There may be punctuate hypopigmented or hyperpigmented scars in between the hyperpigmentation, however, this was not seen in our case.2,4 Differential diagnoses can include livedo reticularis, livedoid vasculitis, flagellate pigmentation, cutaneous T-cell lymphoma and dermatomyositis.5 It is often self-limiting over weeks to months and is managed by avoiding further direct heat exposure to prevent irreversible skin changes such as focal keratinocyte atypia and even reactive angiomatosis.1–3 In some reports, the hyperpigmented skin persisted for years and topical tretinoin, hydroquinone and laser treatments were used successfully.6,7

Acknowledgements David Hugo Romero for his contributions with the graphic design. Dr Miriam Belhadfa for your contribution to this patient’s care.

Contributors JHA, TA, CCK and LHL have all contributed to the manuscript in terms of concept, writing and editing. JHA and LHL were primarily responsible for the concept and design and were part of the treating team. JHA and LHL were responsible for the draft of the manuscript. JHA, TA, CCK and LHL were all responsible for critical revision for important intellectual content and editing of the manuscript and have given final approval of the article for publication. JHA, TA, CCK and LHL have all read and approved the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Consent obtained directly from patient(s).

Provenance and peer review Not commissioned; externally peer reviewed.

Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

ORCID iD
Joshua Haron Abasszade http://orcid.org/0000-0001-5469-4317

REFERENCES

Copyright 2023 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit https://www.bmj.com/company/products-services/rights-and-licensing/permissions/

BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:
► Submit as many cases as you like
► Enjoy fast sympathetic peer review and rapid publication of accepted articles
► Access all the published articles
► Re-use any of the published material for personal use and teaching without further permission

Customer Service
If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.

Visit casereports.bmj.com for more articles like this and to become a Fellow